JP2021502116A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021502116A5 JP2021502116A5 JP2020544130A JP2020544130A JP2021502116A5 JP 2021502116 A5 JP2021502116 A5 JP 2021502116A5 JP 2020544130 A JP2020544130 A JP 2020544130A JP 2020544130 A JP2020544130 A JP 2020544130A JP 2021502116 A5 JP2021502116 A5 JP 2021502116A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- cdr1
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 1016
- 239000000427 antigen Substances 0.000 claims description 116
- 102000036639 antigens Human genes 0.000 claims description 116
- 108091007433 antigens Proteins 0.000 claims description 116
- 102000039446 nucleic acids Human genes 0.000 claims description 35
- 108020004707 nucleic acids Proteins 0.000 claims description 35
- 150000007523 nucleic acids Chemical class 0.000 claims description 35
- 239000013604 expression vector Substances 0.000 claims description 31
- 210000004027 cell Anatomy 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 19
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 6
- 201000009030 Carcinoma Diseases 0.000 claims description 5
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 claims description 5
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 4
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims description 4
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims description 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 4
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 230000004064 dysfunction Effects 0.000 claims description 4
- 210000002865 immune cell Anatomy 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 2
- 206010005003 Bladder cancer Diseases 0.000 claims description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 2
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 2
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 2
- 101000666896 Homo sapiens V-type immunoglobulin domain-containing suppressor of T-cell activation Proteins 0.000 claims description 2
- 102000017578 LAG3 Human genes 0.000 claims description 2
- 101150030213 Lag3 gene Proteins 0.000 claims description 2
- 206010023825 Laryngeal cancer Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 102100038282 V-type immunoglobulin domain-containing suppressor of T-cell activation Human genes 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 210000001072 colon Anatomy 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- IJJVMEJXYNJXOJ-UHFFFAOYSA-N fluquinconazole Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(=O)C2=CC(F)=CC=C2N=C1N1C=NC=N1 IJJVMEJXYNJXOJ-UHFFFAOYSA-N 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 2
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
- 206010023841 laryngeal neoplasm Diseases 0.000 claims description 2
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 206010038038 rectal cancer Diseases 0.000 claims description 2
- 201000001275 rectum cancer Diseases 0.000 claims description 2
- 230000019491 signal transduction Effects 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 2
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 description 12
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
- 206010071541 Metastatic lymphoma Diseases 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023069702A JP7603738B2 (ja) | 2017-11-10 | 2023-04-21 | Ｉｌ２ｒベータ／共通ガンマ鎖抗体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201709289S | 2017-11-10 | ||
| SG10201709289S | 2017-11-10 | ||
| US201862652501P | 2018-04-04 | 2018-04-04 | |
| US62/652,501 | 2018-04-04 | ||
| US201862735347P | 2018-09-24 | 2018-09-24 | |
| US62/735,347 | 2018-09-24 | ||
| PCT/EP2018/080765 WO2019092181A1 (en) | 2017-11-10 | 2018-11-09 | Il2rbeta/common gamma chain antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023069702A Division JP7603738B2 (ja) | 2017-11-10 | 2023-04-21 | Ｉｌ２ｒベータ／共通ガンマ鎖抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021502116A JP2021502116A (ja) | 2021-01-28 |
| JP2021502116A5 true JP2021502116A5 (https=) | 2021-12-23 |
| JP7269249B2 JP7269249B2 (ja) | 2023-05-08 |
Family
ID=64362498
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544130A Active JP7269249B2 (ja) | 2017-11-10 | 2018-11-09 | Ｉｌ２ｒベータ／共通ガンマ鎖抗体 |
| JP2023069702A Active JP7603738B2 (ja) | 2017-11-10 | 2023-04-21 | Ｉｌ２ｒベータ／共通ガンマ鎖抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023069702A Active JP7603738B2 (ja) | 2017-11-10 | 2023-04-21 | Ｉｌ２ｒベータ／共通ガンマ鎖抗体 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11739157B2 (https=) |
| EP (1) | EP3707162A1 (https=) |
| JP (2) | JP7269249B2 (https=) |
| CN (2) | CN111954680B (https=) |
| SG (1) | SG11202004172UA (https=) |
| TW (1) | TWI800552B (https=) |
| WO (1) | WO2019092181A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018089393A1 (en) * | 2016-11-10 | 2018-05-17 | Medimmune, Llc | Binding molecules specific for asct2 and uses thereof |
| TW202031683A (zh) * | 2018-11-09 | 2020-09-01 | 新加坡商優其洛伊生物私人有限公司 | 介白素2受體β(IL2Rβ)/共同γ鏈抗體 |
| TW202039557A (zh) * | 2018-11-09 | 2020-11-01 | 新加坡商優其洛伊生物私人有限公司 | 介白素2受體β(IL2Rβ)/共同γ鏈抗體 |
| CN121319219A (zh) * | 2020-01-14 | 2026-01-13 | 辛德凯因股份有限公司 | Il2突变蛋白 |
| AU2021254283B2 (en) | 2020-04-10 | 2025-12-11 | Cytomx Therapeutics, Inc. | Activatable cytokine constructs and related compositions and methods |
| JP2024511387A (ja) | 2021-03-16 | 2024-03-13 | シートムエックス セラピューティクス，インコーポレイテッド | マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法 |
| TW202304994A (zh) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | 促效性抗ｉｌ－２ｒ抗體及使用方法 |
| GB202115122D0 (en) * | 2021-10-21 | 2021-12-08 | Dualyx Nv | Binding molecules targeting IL-2 receptor |
| CN118251416A (zh) * | 2021-11-02 | 2024-06-25 | 上海岸迈生物科技有限公司 | 抗cd122抗体、抗cd132抗体及相关的双特异性结合蛋白 |
| EP4646225A1 (en) | 2023-01-06 | 2025-11-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| WO2024146955A1 (en) | 2023-01-06 | 2024-07-11 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
| AU2024226225A1 (en) * | 2023-02-20 | 2025-10-09 | Sinomab Bioscience Limited | Anti-common gamma chain proteins and compositions of matter |
| CN116970081B (zh) * | 2023-08-03 | 2024-02-09 | 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) | 一种抗人源cd132的单克隆抗体及其应用 |
| CN118515762B (zh) * | 2024-07-23 | 2024-11-01 | 北京百普赛斯生物科技股份有限公司 | 特异性结合il-2的抗体及其应用 |
| WO2026033139A1 (en) * | 2024-08-09 | 2026-02-12 | Twain Therapeutics Pte. Ltd. | Antigen-binding molecules |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0804578B1 (en) | 1995-01-09 | 2008-07-16 | Boehringer Ingelheim International GmbH | Il-2r-associated polypeptide and dna molecules coding therefor |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| EP0918858A1 (en) * | 1996-05-10 | 1999-06-02 | Biogen, Inc. | Common gamma chain blocking agents |
| WO2011127324A2 (en) * | 2010-04-08 | 2011-10-13 | JN Biosciences, LLC | Antibodies to cd122 |
| CN105143270B (zh) | 2013-02-26 | 2019-11-12 | 罗切格利卡特公司 | 双特异性t细胞活化抗原结合分子 |
| US10259874B2 (en) | 2014-10-27 | 2019-04-16 | Agency For Science, Technology And Research | Anti-TIM-3 antibodies |
| GB201419094D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-TIM-3-antibodies |
| GB201419084D0 (en) | 2014-10-27 | 2014-12-10 | Agency Science Tech & Res | Anti-PD-1 antibodies |
| GB201500319D0 (en) | 2015-01-09 | 2015-02-25 | Agency Science Tech & Res | Anti-PD-L1 antibodies |
| PT3328894T (pt) | 2015-08-06 | 2019-02-13 | Agency Science Tech & Res | Anticorpos de cadeia comum gama/il2rbeta |
| SG10201601719RA (en) | 2016-03-04 | 2017-10-30 | Agency Science Tech & Res | Anti-LAG-3 Antibodies |
| SG10201603721TA (en) | 2016-05-10 | 2017-12-28 | Agency Science Tech & Res | Anti-CTLA-4 Antibodies |
-
2018
- 2018-11-09 CN CN201880086233.4A patent/CN111954680B/zh active Active
- 2018-11-09 JP JP2020544130A patent/JP7269249B2/ja active Active
- 2018-11-09 EP EP18804538.9A patent/EP3707162A1/en active Pending
- 2018-11-09 WO PCT/EP2018/080765 patent/WO2019092181A1/en not_active Ceased
- 2018-11-09 SG SG11202004172UA patent/SG11202004172UA/en unknown
- 2018-11-09 CN CN202410287265.8A patent/CN118373912A/zh active Pending
- 2018-11-09 TW TW107139964A patent/TWI800552B/zh active
- 2018-11-09 US US16/762,895 patent/US11739157B2/en active Active
-
2023
- 2023-04-21 JP JP2023069702A patent/JP7603738B2/ja active Active
- 2023-06-29 US US18/344,214 patent/US20240026016A1/en active Pending
- 2023-06-29 US US18/344,711 patent/US20240052046A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021502116A5 (https=) | ||
| JP2024153803A5 (https=) | ||
| FI3823990T3 (fi) | Cd19:ään sitoutuvia raskasketjun vasta-aineita | |
| JP2018523493A5 (https=) | ||
| RU2018106452A (ru) | Поливалетные и полиспецифичные gitr-связывающие слитые белки | |
| JP2019524693A5 (https=) | ||
| IL264144B2 (en) | Antibody 18A2 against CLAUDIN and its use | |
| US20240342283A1 (en) | ROR1 CAR or ROR1 / CD19 Dual CAR T Cells for the Treatment of Tumors | |
| JP2020531043A5 (https=) | ||
| JP2020516305A5 (https=) | ||
| JP2012501669A5 (https=) | ||
| JP2019536430A5 (https=) | ||
| JP2017515792A5 (https=) | ||
| JP2012501670A5 (https=) | ||
| IL273196B1 (en) | Claudin 6 antibodies and methods of cancer treatment | |
| JP2017506067A5 (https=) | ||
| JP2016536322A5 (https=) | ||
| IL310938A (en) | Anti-CCR8 antibodies and their uses | |
| JP2013527762A5 (https=) | ||
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| CN105194661A (zh) | 时空可调性抑制病理性靶细胞的系统 | |
| JP2014529590A5 (https=) | ||
| JP2022513008A (ja) | 融合タンパク質およびその使用 | |
| JP2021531255A5 (https=) | ||
| JP2016529213A5 (https=) |